(19)
(11) EP 4 823 633 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24827693.3

(22) Date of filing: 12.12.2024
(51) International Patent Classification (IPC): 
A61K 51/04(2006.01)
A61K 45/06(2006.01)
A61K 103/30(2006.01)
 A61K 31/53(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 51/0497; A61K 51/0402; A61K 45/06; A61P 35/00; A61K 31/5377
 
C-Sets:
A61K 31/5377, A61K 2300/00;
(86) International application number:
PCT/EP2024/085997
(87) International publication number:
WO 2025/125469 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.12.2023 EP 23216425

(71) Applicant: Swiss Rockets AG
4052 Basel (CH)

(72) Inventors:
  • CMILJANOVIC, Vladimir
    4304 Giebenach (CH)
  • GRACHEVA, Nadezda
    4304 Giebenach (CH)

(74) Representative: Latscha Schöllhorn Partner AG 
Grellingerstrasse 60
4052 Basel
4052 Basel (CH)

   


(54) COMBINATION THERAPY USING PSMA-TARGETED RADIOPHARMACEUTICALS AND AN INHIBITOR OF PI3K, AKT, AND/OR MTOR